Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients-Reference-Cited by-同舟云学术

Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients

Published:2014-10 Issue:5 Volume:23 Page:637-643
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Berghoff Anna S.,Bartsch Rupert,Preusser Matthias,Ricken Gerda,Steger Guenther G.,Bago-Horvath Zsuzsanna,Rudas Margareta,Streubel Berthold,Dubsky Peter,Gnant Michael,Fitzal Florian,Zielinski Christoph C.,Birner Peter

Funder

Medical University of Vienna

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference44 articles.

1. Effect of screening and adjuvant therapy on mortality from breast cancer;Berry;New Engl J Med,2005

2. Molecular portraits of human breast tumours;Perou;Nature,2000

3. Luminal-B breast cancer and novel therapeutic targets;Tran;Breast Cancer Res BCR,2011

4. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

5. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;New Engl J Med,2001

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance;Cancer Letters;2024-09

2. DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer;EMBO Molecular Medicine;2024-06-17

3. A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer;Acta Pharmacologica Sinica;2024-04-11

4. Overcoming brain-derived therapeutic resistance in HER2+ breast cancer brain metastasis;2024-02-22

5. Quantitative systems pharmacology modeling of HER2-positive metastatic breast cancer for translational efficacy evaluation and combination assessment across therapeutic modalities;Acta Pharmacologica Sinica;2024-02-15